Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Schrödinger auf Morgan Stanley Healthcare-Konferenz: Cloud-Umstellung gewinnt an Fahrt (Investing.com DE) +++ SCHROEDINGER Aktie +5,40%

REGENERON Aktie

 >REGENERON Aktienkurs 
687.3 EUR    +2.0%    (TradegateBSX)
Ask: 688.2 EUR / 0 Stück
Bid: 687 EUR / 0 Stück
Tagesumsatz: 138 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REGENERON Aktie über LYNX handeln
>REGENERON Performance
1 Woche: -3,3%
1 Monat: -0,5%
3 Monate: +29,3%
6 Monate: +5,5%
1 Jahr: +44,0%
laufendes Jahr: +3,6%
>REGENERON Aktie
Name:  REGENERON PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75886F1075 / 881535
Symbol/ Ticker:  RGO (Frankfurt) / REGN (NASDAQ)
Kürzel:  FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN
Index:  S&P500, Nasdaq100
Webseite:  https://www.regeneron.com..
Profil:  Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and met..
>Volltext..
Marktkapitalisierung:  69368.67 Mio. EUR
Unternehmenswert:  64725.53 Mio. EUR
Umsatz:  13393.54 Mio. EUR
EBITDA:  4054.26 Mio. EUR
Nettogewinn:  3732.07 Mio. EUR
Gewinn je Aktie:  36.13 EUR
Schulden:  2333.55 Mio. EUR
Liquide Mittel:  2126.11 Mio. EUR
Operativer Cashflow:  4036.07 Mio. EUR
Bargeldquote:  1.45
Umsatzwachstum:  12.73%
Gewinnwachstum:  0.14%
Dividende je Aktie:  3.18 EUR
Dividendenrendite:  0.47%
Dividendenschätzung:  0.48%
Div. Historie:  18.08.26 - 0.80548596€
20.05.26 - 0.808306€
>weitere anzeigen...
Insiderhandel:  2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.029.974 Euro.
Suchwörter:  REGENERON
Letzte Datenerhebung:  15.09.26
>REGENERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 101.14 Mio. St.
Frei handelbar: 97.95%
Leerverk. Aktien: 2.52%
Rückkaufquote: 3.16%
Mitarbeiter: 15410
Umsatz/Mitarb.: 0.8 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 7.99%
Bewertung:
KGV: 19.24
KGV lG: 14.52
KUV: 5.48
KBV: 2.54
PEG-Ratio: 10.16
EV/EBITDA: 15.96
Rentabilität:
Bruttomarge: 81.46%
Gewinnmarge: 27.86%
Operative Marge: 26.87%
Managementeffizenz:
Gesamtkaprendite: 10.83%
Eigenkaprendite: 14.04%
>REGENERON Peer Group
 
14.09.26 - 20:06
 Regeneron auf Morgan Stanley Konferenz: Wachstum stützt sich auf Dupixent (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
14.09.26 - 18:48
 REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today′s September 14, 2026 Lead Plaintiff Deadline in Securities Class Action (PR Newswire)
 
SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
13.09.26 - 15:30
 REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces (PR Newswire)
 
SAN DIEGO, Sept. 13, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until tomorrow, Monday, September......
10.09.26 - 18:00
 REGN 4-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
10.09.26 - 16:48
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN (PR Newswire)
 
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or......
10.09.26 - 16:15
 SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN (PR Newswire)
 
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FDA Otptimus-related amendments on progression-free survival analysis. NEW YORK, Sept. 10,......
10.09.26 - 13:57
 Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Regeneron to Contact Him Directly to Discuss Their Options NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds......
10.09.26 - 02:18
 REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit (PR Newswire)
 
SAN DIEGO, Sept. 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until September 14,......
09.09.26 - 23:03
 REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure (PR Newswire)
 
SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
09.09.26 - 16:48
 Regeneron auf Wells-Fargo-Konferenz: Wachstum auf breiterer Basis (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
09.09.26 - 16:15
 Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN (PR Newswire)
 
Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure failures that preceded a $102.09 per-share decline from the Class Period high. This notice focuses on fiduciary review, portfolio loss documentation, and lead plaintiff considerations. NEW......
09.09.26 - 13:06
 Recent Stanton graduate wins Humane Science Award from National Anti-Vivisection Society (PR Newswire)
 
Alan Alwakeel among five young scientists worldwide to earn a $3,000 prize at 2026 Regeneron International Science and Engineering Fair JACKSONVILLE, Fla., Sept. 9, 2026 /PRNewswire/ -- Alan Alwakeel, a recent graduate of Stanton College Preparatory School in Jacksonville, Florida, was......
07.09.26 - 19:21
 REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
04.09.26 - 21:00
 Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? (Fool)
 
They could both outperform the market over the medium term, but one appears to have a clear edge....
04.09.26 - 03:01
 Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 340000 USD (Insiderkauf)
 
Guarini, Kathryn - Aufsichtsrat - Tag der Transaktion: 2026-09-02...
04.09.26 - 03:01
 Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 969708 USD (Insiderkauf)
 
Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-03...
04.09.26 - 03:01
 Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 1032750 USD (Insiderkauf)
 
Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-02...
04.09.26 - 01:12
 REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit (PR Newswire)
 
SAN DIEGO, Sept. 3, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until September 14, 2026 to seek......
03.09.26 - 21:21
 REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure (PR Newswire)
 
SAN FRANCISCO, Sept. 3, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
03.09.26 - 16:09
 REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt (PR Newswire)
 
Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged earlier positive trial-risk messaging. NEW YORK, Sept. 3, 2026 /PRNewswire/ -- SueWallSt......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Hora ruit - Die Stunde stürzt dahin. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!